The $130M Bet That CGRP Isn't the Last Word on Migraines
A new startup just raised $130 million to target the migraine pathway that CGRP drugs can't touch. Slate Medicines is betting that PACAP, a completely independent trigger system, could help the millions of patients who don't respond to current therapies.
About half of migraine patients who try the newest class of drugs don't get meaningful relief. That's not a failure stat from the 1990s. That's the reality right now, even after a wave of billion-dollar CGRP therapies (Aimovig, Ajovy, Emgality, Nurtec) reshaped headache medicine over the past seven years.
A brand-new startup called Slate Medicines just raised $130 million to go after the other half.
A New Company, a New Target
Slate launched this week with a $130 million Series A co-led by RA Capital Management, Forbion, and Foresite Capital. The money will fund development of SLTE-1009, an antibody that blocks a protein called PACAP (pituitary adenylate cyclase-activating polypeptide). If that name makes your eyes glaze over, think of it this way: CGRP is like one alarm system that triggers migraines. PACAP is a completely separate alarm, wired through different circuits, that can set off an attack all on its own.
Slate plans to start Phase 1 trials by mid-2026. The drug was licensed from China's DartsBio Pharmaceuticals, making it the latest example of a Western biotech grabbing a clinical asset from a Chinese developer and running it through U.S.-focused trials.
Leading the company is Gregory Oakes, a 30-year biopharma veteran who previously ran Landos Biopharma before AbbVie acquired it. The chief medical officer, Roger Cady, is a headache specialist who held a VP role in neurology at Lundbeck. And Neil Buckley, president and COO, spent eight years at RA Capital's venture arm and has helped launch more than ten companies. This isn't a team learning on the job.
Why CGRP Alone Isn't Enough
Let's give CGRP drugs their credit. They changed the game. Before them, migraine patients were stuck with repurposed blood pressure meds and antidepressants. CGRP-targeting antibodies offered the first therapies actually designed for migraine biology.
But the ceiling is real. Roughly on CGRP antibodies achieve a 50% or greater reduction in monthly migraine days. That sounds decent until you flip it: half the people trying these drugs don't hit that bar. Real-world data paints an even tougher picture, with low 12-month persistence rates across all preventive classes, including the new ones.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
50% of patients
There's also a massive access problem. In many countries, patients must fail multiple older medications before insurers will cover a CGRP therapy. Cost is a factor too; injectable antibodies can run over $500 per month without insurance. And even Nurtec, which analysts expect to hit $1.96 billion in peak sales by 2029, faces patent cliffs in the early 2030s.
The migraine market is projected to reach $16.4 billion across major markets by 2033. Yet the segment everyone is watching now is the one CGRP can't fully serve: patients who've tried these drugs and still suffer.
PACAP: The Parallel Alarm System
So why PACAP? Because it operates through a genuinely independent pathway. In human studies, when researchers infuse PACAP into migraine-prone patients, it triggers attacks. The kicker: it still triggers attacks even when patients are already on a CGRP blocker. That's strong evidence the two systems run in parallel, not in series.
PACAP works through a different set of receptors (PAC1, VPAC1, VPAC2) and activates distinct signaling cascades that dilate blood vessels in the brain's lining and sensitize pain-sensing nerves. Think of CGRP and PACAP as two roads leading to the same miserable destination. Blocking one road helps, but if the other stays wide open, plenty of attacks still get through.
The target has real clinical validation already. Lundbeck's anti-PACAP antibody, bocunebart (Lu AG09222), showed a significant reduction in monthly migraine days versus placebo in a Phase 2 trial; treated patients saw roughly 6 fewer migraine days per month compared to about 4.2 for placebo. Lundbeck has since completed a larger Phase 2b dose-finding study called PROCEED, with results already publicly disclosed.
Eli Lilly also tested a PACAP antibody (LY3451838) in treatment-resistant patients. The primary endpoints didn't reach statistical significance, but the numbers trended in the right direction, especially in chronic migraine patients who saw 4.7 fewer monthly migraine days versus 3.0 for placebo.
Notably, an earlier approach that targeted just the PAC1 receptor (Amgen's AMG 301) flopped in trials. The field has since pivoted toward blocking the PACAP protein itself, which is exactly what Slate's SLTE-1009 is designed to do.
The China Pipeline, American Wrapper
Slate's licensing deal with DartsBio fits a pattern that's become impossible to ignore. Cross-border licensing deals for Chinese biotech products jumped from 42 in 2022 to 93 in 2025. U.S. drugmakers alone signed 14 China-sourced deals worth $18.3 billion in the first half of 2025, up from just two such deals in the same period of 2024.
The economics have shifted too. Average upfront payments on these deals have surged from $52 million in 2022 to $172 million in early 2026, a 230% increase. China is no longer the bargain bin of biotech; it's become a primary source of differentiated clinical assets, particularly in antibody drug conjugates, bispecifics, and now apparently migraine biology.
Slate's structure reflects the modern playbook: license a promising early-stage molecule from a Chinese developer, surround it with experienced Western operators, and aim for rapid clinical development under a U.S. regulatory framework. The company was co-founded through RA Capital's Sera Medicines platform, which is essentially a biotech incubator designed to spin out exactly this kind of venture.
The Risks Are Real
Let's be clear about what Slate doesn't have yet: any human data for SLTE-1009. The company hasn't disclosed detailed preclinical results, receptor selectivity profiles, or functional data. Phase 1 hasn't started. For a $130 million bet, investors are relying heavily on class-level evidence from Lundbeck and Lilly, plus whatever proprietary data DartsBio generated before the deal.
The competitive landscape also matters. If Lundbeck's bocunebart continues to post strong results and reaches the market first, Slate would need to demonstrate a clear advantage, whether that's better dosing convenience (SLTE-1009 is designed for subcutaneous injection with half-life extension), superior efficacy, or a cleaner safety profile.
And there's the broader question of whether PACAP blockade will prove as commercially important as the science suggests. PACAP therapies are likely headed for a focused role in post-CGRP-failure patients rather than mass adoption.
The Bottom Line
Slate Medicines is a well-funded, well-staffed bet on a simple thesis: CGRP was chapter one of modern migraine treatment, not the whole book. The science behind PACAP is solid. The unmet need is undeniable. The team has done this before.
But SLTE-1009 is still pre-clinical. Phase 1 is months away. And the road from a promising target to an approved drug is littered with antibodies that looked great on paper. Slate's $130 million buys them a shot, not a guarantee. The migraine patients waiting for something better are watching closely, whether they know it or not.
Clinical & Regulatory
5 min read
The FDA Just Declared War on Cheap Ozempic
The FDA just launched its largest-ever coordinated crackdown on compounding pharmacies selling cheap versions of Ozempic and Wegovy, explicitly targeting Hims & Hers in the process. A multibillion-dollar grey market is being dismantled, and the fallout is reshaping telehealth, Big Pharma, and patient access to the most popular drugs in America.
